Vincent has close to 50 years’ experience in the biotechnology industry in a broad range of functions. He helps identify and evaluate new business opportunities and supports portfolio companies. His more recent Board positions have included Brave Bio, IFM Therapeutics, IFM Tre, IFM Due, Personalis and Hydra Biosciences, and he has also been an observer on the Boards of Nido Biosciences and Atsena Therapeutics. Earlier Board positions included Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Magellan Diagnostics and PrimeraDx.
Before joining Abingworth in 2007 he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company). Previously, Vincent was at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was head of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International.
Vincent has a BSc in Biochemistry and a PhD in Biochemical Embryology (molecular biology) from University College London. Vincent has also been elected an Associate Fellow of the Royal Historical Society in recognition of his books and articles on maritime history.
